ANN ARBOR, Mich.--(BUSINESS WIRE)--Atterocor, Inc., a company developing a novel therapy for adrenal cancer, today announced three poster presentations on ATR-101 at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo, being held Mar. 5-8 at the San Diego Convention Center in San Diego. ATR-101 is the company’s novel, oral drug candidate in a Phase 1 clinical study for the treatment of adrenocortical carcinoma (ACC). ATR-101 is a selective inhibitor of ACAT1, which reduces adrenal steroids and induces apoptosis of cells derived from the adrenal cortex.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
